Head-to-head evidence
HD204 vs LY01008
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
HD204
Developed by Prestige Biopharma Limited
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
LY01008
Developed by Luye Pharma Group
NCT03533127 · Phase 3 · status unknown
This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HD204's landscape · LY01008's landscape